Manulife (Manufacturers Life Insurance)
ACRS icon

Manulife (Manufacturers Life Insurance)’s Aclaris Therapeutics ACRS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Buy
32,406
+7,008
+28% +$31.3K ﹤0.01% 2618
2026
Q1 		$95.2K Sell
25,398
-3,600
-12% -$12.1K ﹤0.01% 2636
2025
Q4 		$87.3K Sell
28,998
-4,502
-13% -$11.4K ﹤0.01% 2734
2025
Q3 		$63.6K Sell
33,500
-631
-2% -$1.1K ﹤0.01% 2853
2025
Q2 		$48.5K Buy
+34,131
New +$46.2K ﹤0.01% 2891
2024
Q2 		– Sell
-14,788
Closed -$18.3K – 2961
2024
Q1 		$18.3K Sell
14,788
-1,172
-7% -$1.4K ﹤0.01% 2930
2023
Q4 		$16.8K Sell
15,960
-12,014
-43% -$36.7K ﹤0.01% 2947
2023
Q3 		$192K Buy
27,974
+507
+2% +$4.33K ﹤0.01% 2627
2023
Q2 		$285K Buy
27,467
+2,541
+10% +$23K ﹤0.01% 2401
2023
Q1 		$202K Hold
24,926
– – ﹤0.01% 2566
2022
Q4 		$393K Buy
24,926
+1,539
+7% +$24.8K ﹤0.01% 2137
2022
Q3 		$368K Sell
23,387
-448
-2% -$7.06K ﹤0.01% 2171
2022
Q2 		$333K Buy
23,835
+2,640
+12% +$37K ﹤0.01% 2328
2022
Q1 		$365K Sell
21,195
-5,300
-20% -$72.3K ﹤0.01% 2387
2021
Q4 		$385 Sell
26,495
-84
-0.3% -$1.27K ﹤0.01% 2443
2021
Q3 		$478K Buy
26,579
+1,864
+8% +$29.9K ﹤0.01% 2321
2021
Q2 		$434K Buy
+24,715
New +$561K ﹤0.01% 2540
2019
Q2 		– Sell
-25,617
Closed -$153K – 2902
2019
Q1 		$153K Buy
25,617
+12,288
+92% +$81.5K ﹤0.01% 2501
2018
Q4 		$99K Buy
13,329
+2,695
+25% +$27.8K ﹤0.01% 2440
2018
Q3 		$154K Sell
10,634
-10,367
-49% -$178K ﹤0.01% 2829
2018
Q2 		$420K Buy
21,001
+2,866
+16% +$53K ﹤0.01% 2528
2018
Q1 		$317K Sell
18,135
-198
-1% -$4.2K ﹤0.01% 2674
2017
Q4 		$452K Buy
18,333
+725
+4% +$17.7K ﹤0.01% 2386
2017
Q3 		$455K Buy
17,608
+1,777
+11% +$47.6K ﹤0.01% 2336
2017
Q2 		$429K Buy
15,831
+6,502
+70% +$177K ﹤0.01% 2410
2017
Q1 		$278K Buy
9,329
+1,567
+20% +$45.2K ﹤0.01% 2603
2016
Q4 		$211K Buy
7,762
+242
+3% +$6.17K ﹤0.01% 2739
2016
Q3 		$192K Hold
7,520
– – ﹤0.01% 2803
2016
Q2 		$139K Buy
7,520
+3,410
+83% +$67.6K ﹤0.01% 3010
2016
Q1 		$64K Buy
+4,110
New +$78.5K ﹤0.01% 3215

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ACRS Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Aclaris Therapeutics (ACRS) stake by 28% in Q2 2026, buying an estimated $31.3K and bringing the position to 32,406 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Manulife (Manufacturers Life Insurance) first reported a position in ACRS in Q1 2016 and has held it in 30 quarters since. The position peaked at $478K in Q3 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 32,406 shares of Aclaris Therapeutics worth $171K as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) bought 7,008 Aclaris Therapeutics shares in Q2 2026, an estimated $31.3K.
  • Aclaris Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #2618 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Aclaris Therapeutics in Q1 2016 and has held it in 30 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Aclaris Therapeutics position peaked at $478K in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.